LONDON (Alliance News) - Collagen Solutions PLC said Thursday that its product Excellagen has been selected for a Phase Ib safety study for the treatment of chronic diabetic wounds, to be funded by a project called Reddstar.
The project has received more than EUR5 million from the European Union in funding.
Excellagen is based on bovine collagen, and has been cleared by the US Food and Drug Administration for the treatment of chronic non-healing skin wounds.
The product will be used in combination with Orbsen Therapeutics Ltd's Cyndacel-M's stem cell therapy.
The study is being coordinated at Ireland's Regenerative Medicine Institute at the National University of Ireland Galway.
Shares in Collagen Solutions were trading up 2.5% at 9.35 pence Thursday afternoon.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
